HURA TuHURA Biosciences (HURA) Insider Trading, Ownership & Congress Trades
Pharma & Biotech · Pharmaceutical preparations · CIK 0001498382
SEC filings
Insider buyers, 180 days
0
House members buying, 1 year
0
STOCK Act, US House only, disclosed up to 45 days after the trade
Funds added, last quarter
38
13F, latest reported quarter
What the filings say about HURA
Congress, 1 year
No trades
Last one: purchase, 2025-07-13
TuHURA Biosciences insider trades (Form 4)
Form 4 buys and sells (codes P and S). Grants, option exercises
and conversions excluded.
No insider purchases or sales are on record for TuHURA Biosciences, Inc./NV in the period covered. Source: SEC Form 4 filings, as of 2026-10-28.
Insider
Filed
Shares
Value
Since filing
no insider purchases or sales on record
0 transactions on record
Seven facts, ranked against the sector ·
Rank is not a forecast
Insiders
no insider buys or sells on file
Congress
no House purchase disclosed in the last 12 months
Funds
38 funds bought in last quarter
below 58% of Pharma & Biotech
Revenue
no revenue reported in any filing
Margin
no margin: no revenue reported
Buybacks
no share repurchases reported
Short interest
15.3% of the float short (float per yahoo 2026-10-26) · 28.4 days to cover · settled 2026-09-30
more than 70% of Pharma & Biotech
What changed in the last 30 days
Nothing new filed in the last 30 days
Watch HURA
A free account keeps a watchlist and can send one email a day when insiders, funds or Congress file on the names in it. No password and no card.
The year, with the filings on it
Total return over 12 months. Each marker is a filing; hover or tap one for the detail.
-8.5%12M
Indexed to 100, dividend-adjusted, not a price chart.
When a name files heavily, the largest trades are drawn first.
Who owns HURA: institutional holders (13F)
13F holdings, latest reported quarter
2,267,901 sh
$5.3M
1,621,042 sh
$3.8M
690,088 sh
$1.6M
484,219 sh
$1.1M
454,535 sh
$1.1M
Congress trades in HURA
STOCK Act disclosures, US House only, filed up to 45 days after the trade
Bought 2025-07-13 · disclosed 27 days later
$50,001 - $100,000
Bought 2024-11-25 · disclosed 43 days later
$1,001 - $15,000
Exchanged 2024-10-18 · disclosed 34 days later
$100,001 - $250,000
Activist and 5% holders (13D/13G)
No 5%+ ownership filings
Nobody has filed for crossing 5%. That is a fact, not missing data.
HURA planned insider sales (Form 144)
No planned-sale notices
No insider has filed to sell. Watch this after a run-up.
HURA mutual fund holders (N-PORT)
Funds ranked by the share of their own portfolio in this stock (N-PORT).
iShares Micro-Cap ETF
$383.1K position · as of 2026-06-30
0.0%
1290 VT Micro Cap Portfolio
$25.8K position · as of 2026-06-30
0.0%
VANGUARD RUSSELL 2000 GROWTH INDEX FUND
$90.4K position · as of 2026-05-31
0.0%
VANGUARD RUSSELL 2000 INDEX FUND
$495.7K position · as of 2026-05-31
0.0%
Small Cap Index Fund
$33.8K position · as of 2026-05-31
0.0%
ProShares Russell 2000 High Income ETF
$4.6K position · as of 2026-05-31
0.0%
SEC N-PORT, monthly, about 60 days late · funds ≥ $10M ·
% is the share of the fund's own portfolio
Clinical pipeline
5 registered trials, 2 still running (ClinicalTrials.gov).
A status change is dated here weeks before the press release.
3
Phase 1
1 active
1
Not applicable
0 active
1
Multi-phase
1 active
What changed recently
IFx-Hu2.0 As An Adjunctive Therapy To Pembrolizumab In Advanced Or Metastatic Merkel Cel
2026-10-22 · Completion moved 2026-05-31 → 2027-04
Phase 1
Matched by sponsor name. Trials run under a subsidiary's
own name are not included.
Executive pay vs shareholder return · Dr Bianco
CEO pay, headline and as actually paid, against the company's
return and its chosen peers' (DEF 14A).
FY
CEO total
Actually paid
Other execs, avg
TSR
Peer TSR
2025
$4.0M
$1.8M
$1.8M
n/a
n/a
2022
$1.2M
$559.0K
$332.2K
-96%
n/a
Tagged by the company under SEC Item 402(v). Returns are
cumulative from the start of the disclosure period. Green where the company beat its own peer group.
Live price
Daily candles from TradingView, under their licence. No filings marked.
Why this name is on the desk
The complete filing record, in one place.
The record shows 38 funds added last quarter. Each figure is a federal filing, dated the day it went public.
HURA financials
Ratios from the company's XBRL filings, latest filings
Revenue, TTM
$0
four quarters, 2025-04-01 to 2026-03-31
Revenue, TTM HURA
| FY Dec 2025 | $0 |
| FY Dec 2024 | $0 |
| FY Jun 2024 | n/a |
| FY Dec 2023 | n/a |
| FY Jun 2023 | n/a |
| Jun 2026 | n/a |
| Mar 2026 | $0 |
| Dec 2025 | $0 |
| Sep 2025 | $0 |
| Jun 2025 | $0 |
| Mar 2025 | $0 |
| Dec 2024 | $0 |
| Sep 2024 | $0 |
At each fiscal year end
Single quarter
Net margin, TTM
n/a
revenue under $1M, the ratio says nothing
Net margin, TTM HURA
| FY Dec 2025 | n/a |
| FY Dec 2024 | n/a |
| FY Jun 2024 | n/a |
| FY Dec 2023 | n/a |
| FY Jun 2023 | n/a |
| Jun 2026 | n/a |
| Mar 2026 | n/a |
| Dec 2025 | n/a |
| Sep 2025 | n/a |
| Jun 2025 | n/a |
| Mar 2025 | n/a |
| Dec 2024 | n/a |
| Sep 2024 | n/a |
At each fiscal year end
Single quarter
Free cash flow, TTM
-$29.9M
operating cash flow minus capex, 2025-07-01 to 2026-06-30
Free cash flow, TTM HURA
| FY Dec 2025 | -$27.7M |
| FY Dec 2024 | n/a |
| FY Jun 2024 | n/a |
| FY Dec 2023 | n/a |
| FY Jun 2023 | -$12.1M |
| Jun 2026 | -$8.8M |
| Mar 2026 | -$4.5M |
| Dec 2025 | -$5.6M |
| Sep 2025 | -$11.1M |
| Jun 2025 | -$6.3M |
| Mar 2025 | -$4.8M |
| Dec 2024 | -$2.6M |
| Sep 2024 | -$1.9M |
At each fiscal year end
Single quarter
Debt to equity
0.19x
LongTermDebt as filed 2026-06-30 (includes the current portion); equity 2026-06-30
Debt to equity HURA
| FY Dec 2025 | 0.00x |
| FY Dec 2024 | 0.00x |
| FY Jun 2024 | n/a |
| FY Dec 2023 | n/a |
| FY Jun 2023 | 0.00x |
| Jun 2026 | 0.19x |
| Mar 2026 | 0.00x |
| Dec 2025 | 0.00x |
| Sep 2025 | 0.00x |
| Jun 2025 | 0.00x |
| Mar 2025 | 0.00x |
| Dec 2024 | 0.00x |
| Sep 2024 | n/a |
At each fiscal year end
Trailing four quarters at each quarter end
Cash flow to debt
-8.25x
TTM operating cash flow over LongTermDebt as filed 2026-06-30 (includes the current portion)
Cash flow to debt HURA
| FY Dec 2025 | -104,260.94x |
| FY Dec 2024 | n/a |
| FY Jun 2024 | n/a |
| FY Dec 2023 | n/a |
| FY Jun 2023 | -44,773.58x |
| Jun 2026 | -8.25x |
| Mar 2026 | -103,032.76x |
| Dec 2025 | -104,260.94x |
| Sep 2025 | n/a |
| Jun 2025 | n/a |
| Mar 2025 | n/a |
| Dec 2024 | n/a |
| Sep 2024 | n/a |
At each fiscal year end
Trailing four quarters at each quarter end
Return on equity
-166.4%
TTM net income over average of 2025-06-30 and 2026-06-30
Return on equity HURA
| FY Dec 2025 | -174.5% |
| FY Dec 2024 | n/a |
| FY Jun 2024 | n/a |
| FY Dec 2023 | n/a |
| FY Jun 2023 | -233.9% |
| Jun 2026 | -166.4% |
| Mar 2026 | -192.9% |
| Dec 2025 | -174.5% |
| Sep 2025 | -436.9% |
| Jun 2025 | -465.6% |
| Mar 2025 | n/a |
| Dec 2024 | n/a |
| Sep 2024 | n/a |
At each fiscal year end
Trailing four quarters at each quarter end
Return on assets
-95.1%
TTM net income over average of 2025-06-30 and 2026-06-30
Return on assets HURA
| FY Dec 2025 | -131.0% |
| FY Dec 2024 | n/a |
| FY Jun 2024 | n/a |
| FY Dec 2023 | n/a |
| FY Jun 2023 | -147.0% |
| Jun 2026 | -95.1% |
| Mar 2026 | -143.8% |
| Dec 2025 | -131.0% |
| Sep 2025 | -205.1% |
| Jun 2025 | -142.5% |
| Mar 2025 | n/a |
| Dec 2024 | n/a |
| Sep 2024 | n/a |
At each fiscal year end
Trailing four quarters at each quarter end
Return on invested capital
n/a
fewer than four consecutive quarters of operating income
Return on invested capital HURA
| FY Dec 2025 | n/a |
| FY Dec 2024 | n/a |
| FY Jun 2024 | n/a |
| FY Dec 2023 | n/a |
| FY Jun 2023 | n/a |
| Jun 2026 | n/a |
| Mar 2026 | n/a |
| Dec 2025 | n/a |
| Sep 2025 | n/a |
| Jun 2025 | n/a |
| Mar 2025 | n/a |
| Dec 2024 | n/a |
| Sep 2024 | n/a |
At each fiscal year end
Trailing four quarters at each quarter end
Return on capital employed
n/a
fewer than four consecutive quarters of operating income
Return on capital employed HURA
| FY Dec 2025 | n/a |
| FY Dec 2024 | n/a |
| FY Jun 2024 | n/a |
| FY Dec 2023 | n/a |
| FY Jun 2023 | n/a |
| Jun 2026 | n/a |
| Mar 2026 | n/a |
| Dec 2025 | n/a |
| Sep 2025 | n/a |
| Jun 2025 | n/a |
| Mar 2025 | n/a |
| Dec 2024 | n/a |
| Sep 2024 | n/a |
At each fiscal year end
Trailing four quarters at each quarter end
P/E, trailing
n/a
trailing loss, a multiple of a loss is not meaningful
P/E, trailing HURA
| FY Dec 2025 | n/a |
| FY Dec 2024 | n/a |
| FY Jun 2024 | n/a |
| FY Dec 2023 | n/a |
| FY Jun 2023 | n/a |
| Jun 2026 | n/a |
| Mar 2026 | n/a |
| Dec 2025 | n/a |
| Sep 2025 | n/a |
| Jun 2025 | n/a |
| Mar 2025 | n/a |
| Dec 2024 | n/a |
| Sep 2024 | n/a |
At each fiscal year end
Trailing four quarters at each quarter end
Enterprise value
$132.6M
market value at close 2026-10-26 on 2026-08-11 shares, plus LongTermDebt as filed 2026-06-30 (includes the current portion), minus cash 2026-06-30
Enterprise value HURA
| FY Dec 2025 | $35.2M |
| FY Dec 2024 | $172.9B |
| FY Jun 2024 | $522.6B |
| FY Dec 2023 | $20.2B |
| FY Jun 2023 | $237.1M |
| Jun 2026 | $151.6M |
| Mar 2026 | $107.5M |
| Dec 2025 | $35.2M |
| Sep 2025 | $121.4M |
| Jun 2025 | $88.9M |
| Mar 2025 | $134.9M |
| Dec 2024 | $172.9B |
| Sep 2024 | $377.5B |
At each fiscal year end
Trailing four quarters at each quarter end
FCF yield
-23.0%
TTM free cash flow over market value at close 2026-10-26
FCF yield HURA
| FY Dec 2025 | -71.4% |
| FY Dec 2024 | n/a |
| FY Jun 2024 | n/a |
| FY Dec 2023 | n/a |
| FY Jun 2023 | -5.1% |
| Jun 2026 | -20.1% |
| Mar 2026 | -24.1% |
| Dec 2025 | -71.4% |
| Sep 2025 | n/a |
| Jun 2025 | n/a |
| Mar 2025 | n/a |
| Dec 2024 | n/a |
| Sep 2024 | n/a |
At each fiscal year end
Trailing four quarters at each quarter end
PEG, trailing
n/a
trailing loss, a multiple of a loss is not meaningful
PEG, trailing HURA
| FY Dec 2025 | n/a |
| FY Dec 2024 | n/a |
| FY Jun 2024 | n/a |
| FY Dec 2023 | n/a |
| FY Jun 2023 | n/a |
| Jun 2026 | n/a |
| Mar 2026 | n/a |
| Dec 2025 | n/a |
| Sep 2025 | n/a |
| Jun 2025 | n/a |
| Mar 2025 | n/a |
| Dec 2024 | n/a |
| Sep 2024 | n/a |
At each fiscal year end
Trailing four quarters at each quarter end
Price as of 2026-10-26. Hover or tap a tile for its yearly and quarterly history.
Method
TTM is four consecutive fiscal quarters; Q4 is the year minus nine months when not filed. Returns use the average of opening and closing balances. EBIT is approximated by operating income. PEG uses trailing EPS growth.
Fundamentals
Annual figures from XBRL filings. Pick a past date to see them as known then.
| 2025-12 | 2024-12 | 2024-06 | 2023-12 | |
|---|---|---|---|---|
| Revenue | $0 | $0 | n/a | $0 |
| Net income | -$31.0M | -$23.0M | -$8.3M | -$15.0M |
| EPS (diluted) | -0.63 | -1.21 | n/a | -2.47 |
| Operating cash flow | -$27.6M | -$14.7M | -$7.2M | -$12.0M |
| Cash | $3.6M | $12.7M | $4.9M | $3.7M |
| Buybacks | n/a | n/a | n/a | $24.8K |
SEC XBRL, fiscal years, as known on 2026-10-28
HURA Stock Sonar score 4/7 axes
Find similar shapesCompareHURA ranks highest on risk and compliance (51st percentile) and institutional and government (42nd), and lowest on profitability (23rd), among Pharma & Biotech peers.
4 of 7 axes scored. Each is a percentile against sector peers (all companies when the sector is thin); higher is better. An unscored axis is unmeasured, not low. How it is scored
HURA filings, in plain words
Have members of Congress traded HURA?
Yes, but not in the year to 2026-10-28; the latest on record is a purchase by Laurel Lee dated 2025-07-13.
Read the full summary
Members of Congress have disclosed trades in HURA, none in the last year; the latest on record is a purchase by Laurel Lee dated 2025-07-13. Each figure is counted from SEC and House filings as of 2026-10-28, dated the day the filing was made public.
Explore insider trading and ownership data
Every company we track, ranked by each kind of filing
